Diagnostics company Thyrocare Technologies felt the blow of demonetisation in the month of November but was back on its feet and saw growth at 24 percent in the month under review.
USFDA has issued notice to the Hyderabad unit of Aurobindo Pharma and calming the nerves of the investors Surajit Pal of Prabhudas Lilladher says that it is a non-event and there is no need to worry.
A regulatory body for labs could help the unorganised sector as well as help mitigate risks for companies, says A Velumani, Chairman, CEO & MD of the company.
Thyrocare neither has any revenue share agreement with doctors nor does it pay them any commissions to send patients to their laboratories, says CMD A Velumani.